Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Cemiplimab + ISA101b |
Indication/Tumor Type | oropharynx cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | oropharynx cancer | predicted - sensitive | Cemiplimab + ISA101b | Phase II | Actionable | In a Phase II trial, ISA101b and Libtayo (cemiplimab) combination treatment demonstrated safety in patients with HPV16-positive oropharynx cancer and resulted in an overall response rate (ORR) that did not significantly differ from placebo plus Libtayo (cemiplimab) in the full analysis set (25.3 vs 22.9%, p=0.590), but in CD274 (PD-L1)-positive patients in the per protocol set (CPS>/=20), the ORR was significantly improved (61.9 vs 28.0%, p=0.026) (J Clin Oncol 42, 2024 (suppl 16; abstr 6003); NCT03669718). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC). | Full reference... |